| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
VAXXITEK® HVT+ IBD
Record information and status
Record ID
109735
Status
Published
Date of creation
2016-02-25 20:27 UTC (gutemberg.sousa@mcti.gov.br)
Date of publication
2016-02-26 21:04 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
VAXXITEK® HVT+ IBD
Transformation event
vHTV013-69
Developer(s)
Dra Luciana Fernanda Matias Soares
President of Internal Biosafety Commission
Animal Health
Merial Saúde Animal Ltda (Merial)
Fazenda São Francisco s/nº - Caixa Postal: 242 - PAULINIA (SP)
Paulínia, São Paulo
Brazil, 13140970
Phone:+55 19 3874-8601
Fax:+55 19 3874-8080
Email:luciana.soares@merial.com.br
Url:Merial
Description
Vaxxitek HVT + IBD is a live vaccine based on the use of a recombinant turkey Herpesvirus (HVT) expressing the VP2 gene of the Infectious Bursal Disease (Gumboro disease) Virus (IBDV).

This vaccine contains a live strain of serotype 3 vectored virus that has been shown to aid in the prevention of Bursal disease and Marek's disease.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Meleagrid herpesvirus 1 - Turkey Herpesvirus
Point of collection or acquisition of the recipient organism
Meleagrid herpesvirus 1 (HVT) strain: FC-126
Related LMOs
VECTORMUNE® HVT-IBD
Dr Alexis Henry Gaetan Goux Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Characteristics of the transformation process
Vector
vHVT013-69
Techniques used for the modification
  • Homologous Recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Viral Protein 2 gene - Infectious bursal disease virus - Gumboro virus
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
Vaxxitek HVT + IBD vaccine is a live recombinant vaccine against Gumboro disease (or infectious bursal disease) and Marek's disease in chickens. It is a frozen vaccine to be diluted with an aqueous diluent. The active ingredient is the production-cell associated vHVT013-69 virus vaccine strain, a recombinant turkey Herpesvirus (HVT) expressing the VP2 coding sequence of Infectious Bursal Disease Virus (IBDV). The parental strain of Vaxxitek HVT + IBD (named FC-126) belongs to the serotype 3 of Marek's disease and is widely used in classical vaccination against Marek's disease. HVT strains are apathogenic in all species, and do not replicate in mammalian cells. The inserted sequence corresponds to the sequence coding for the VP2 protein of Infectious Bursal Disease Virus (IBDV). It has been cloned from 52/70 Faragher strain. The VP2 protein is the only protein of IBDV that induces protection against Gumboro disease.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine
Additional Information
Other relevant website address or attached documents

Records referencing this document (2)
IDDescription
2record(s) found
Country's Decision or any other Communication1 record
Risk Assessment1 record